SCHEDULE: Avoro Capital Discloses 8.3% Stake in Arrowhead Pharma

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 8.3% in Arrowhead Pharmaceuticals, Inc., holding over 11.5 million shares.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh collectively beneficially own 11,517,441 shares of Arrowhead Pharmaceuticals, Inc. Common Stock.
• This ownership represents 8.3% of the company's outstanding Common Stock.
• The total shares include 917,441 shares issuable upon the exercise of warrants.
• The percentage is calculated based on 138,100,435 shares of Common Stock outstanding as of May 1, 2025, as reported in the company's Form 10-Q filed on May 12, 2025.
• The shares were acquired and are held solely for investment purposes, not with the intent to change or influence control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral in its direct content as it's a disclosure of ownership. However, a significant stake by a specialized investment firm like Avoro Capital Advisors can be interpreted as a positive signal of confidence in Arrowhead Pharmaceuticals' long-term value, hence a slightly positive score.

Positives

• A significant stake by an investment advisor (Avoro Capital Advisors LLC) and its controlling person (Behzad Aghazadeh) may signal confidence in Arrowhead Pharmaceuticals' long-term prospects.
• The investment is stated to be for 'investment purposes,' suggesting a passive, long-term view rather than an activist stance.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a specialized life sciences fund in a biotechnology company, which is common in the pharmaceutical sector where long-term investments are made based on pipeline potential and market opportunities.

Comparison to Industry Standards

• The 8.3% stake is a substantial passive investment, typical for institutional investors in the biotech sector who aim for long-term capital appreciation.
• Comparable to other investment funds like ARK Invest or BlackRock's specialized funds that take significant, non-controlling stakes in emerging pharmaceutical companies based on their R&D pipelines and market potential.
• For example, a similar stake might be seen in companies like Moderna (MRNA) or BioNTech (BNTX) during their early growth phases, where large funds bet on future drug approvals.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.
• Management: Awareness of a large, passive investor on the shareholder register.

Key Dates

Recommendation

This filing primarily discloses a significant passive ownership stake by Avoro Capital Advisors and Behzad Aghazadeh in Arrowhead Pharmaceuticals. While the acquisition of an 8.3% stake by a specialized life sciences fund could be seen as a vote of confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It indicates a long-term investment purpose, suggesting the current holders are maintaining their position. Therefore, a 'hold' recommendation is appropriate as there's no new information to fundamentally change the investment thesis, but the presence of a significant institutional investor might provide some stability.

Keywords

Arrowhead Pharmaceuticals, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment